Evidence map›Paper›PMID 32873644›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models.

Deli Huang, Robert K Abbott, Colin Havenar-Daughton, Patrick D Skog, Rita Al-Kolla, Bettina Groschel, Tanya R Blane, Sergey Menis, Jenny Tuyet Tran, Theresa C Thinnes and 16 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Blunting specific T-dependent antibody responses with engineered "decoy" B cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 3 institutions in 1 country.

Deli HuangDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-6989-639X
Robert K AbbottCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037.
Colin Havenar-DaughtonCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037.
Patrick D SkogDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-5759-5071
Rita Al-KollaCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037.ORCID 0000-0003-3749-2320
Bettina GroschelDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0003-3127-5448
Tanya R BlaneDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Sergey MenisDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Jenny Tuyet TranDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Theresa C ThinnesDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Sabrina A VolpiDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-3116-3465
Alessia LiguoriDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Torben SchiffnerDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Sophia M VillegasDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Oleksandr KalyuzhniyDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-5273-1951
Mark PinteaDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
James E VossDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Nicole PhelpsDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Ryan TingleDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Alberto R RodriguezDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-9677-1752
Greg MartinDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0003-4647-8627
Sergey KupryianovDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Allan deCampVaccine and Infectious Disease Division, Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109.
William R SchiefDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-1120-0150
David NemazeeDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037; nemazee@scripps.edu shane@lji.org.ORCID 0000-0002-4769-6311
Shane CrottyCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037; nemazee@scripps.edu shane@lji.org.ORCID 0000-0002-6484-6262
Scripps Research Institute · USFred Hutch Cancer Center · USLa Jolla Institute for Immunology · US

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Knock-in mice expressing germline-reverted broadly neutralizing HIV antibodiesR01AI073148 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 2007 to 2023
$8.2M
Designing and optimizing candidate HIV vaccines and boosting protocolsR01AI128836 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 2017 to 2021
$4.8M
Training in Immunological MechanismsT32AI125179 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2016 to 2025
$3.1M
Mapping the germinal center and memory B cell landscape to complex antigensK99AI145762 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI ABBOTT, ROBERT KOEHLER · 2019 to 2020
$265k
NIAID NIH HHS K99 AI145762NIAID NIH HHS R01 AI073148NIAID NIH HHS R01 AI128836NIAID NIH HHS T32 AI125179NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

Animal models of human antigen-specific B cell receptors (BCRs) generally depend on "inferred germline" sequences, and thus their relationship to authentic naive human B cell BCR sequences and affinities is unclear. Here, BCR sequences from authentic naive human VRC01-class B cells from healthy human donors were selected for the generation of three BCR knockin mice. The BCRs span the physiological range of affinities found in humans, and use three different light chains (VK3-20, VK1-5, and VK1-33) found among subclasses of naive human VRC01-class B cells and HIV broadly neutralizing antibodies (bnAbs). The germline-targeting HIV immunogen eOD-GT8 60mer is currently in clinical trial as a candidate bnAb vaccine priming immunogen. To attempt to model human immune responses to the eOD-GT8 60mer, we tested each authentic naive human VRC01-class BCR mouse model under rare human physiological B cell precursor frequency conditions. B cells with high (HuGL18

Indexed as

AIDS VaccinesAmino Acid SequenceAnimalsAntibodies, MonoclonalAntibodies, NeutralizingB-LymphocytesBroadly Neutralizing AntibodiesCD4 AntigensGene Knock-In TechniquesGerminal CenterHIV-1HIV AntibodiesHIV AntigensHIV InfectionsHumansMiceAIDS VaccinesAntibodies, MonoclonalAntibodies, NeutralizingBroadly Neutralizing AntibodiesCD4 AntigensHIV AntibodiesHIV AntigensReceptors, Antigen, B-CellVRC01 monoclonal antibodygerminal centergermline targetingHIVimmunodominancevaccine

Identifiers

PMID32873644
PMCPMC7502816
OpenAlexW3082685454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.